U.S. stocks experienced a strong comeback on Friday, with the S&P 500 index rising 1.59%, reversing a previous decline triggered by concerns about the impact of Donald Trump's tariffs on the world's largest economy.
Despite a difficult period for the biotech sector, Jefferies analyst Michael Yee sees opportunities for growth. According to his analysis, many biotech companies are trading below their cash value, presenting attractive investment opportunities for those who can identify the right catalysts, such as clinical trials, regulatory approvals and strategic launches.
Jefferies analysts have identified two biotech companies that have the potential to soar - one of which could jump as much as 500%.
Alto Neuroscience $ANRO
Alto Neuroscience is a clinical-stage biotechnology company focused on treating central nervous system (CNS) disorders and psychiatric diseases. It uses the principles of precision medicine to develop treatments for difficult-to-treat conditions such as depression,…